VHL Syndrome Q&A with Roswell Park Comprehensive Cancer Center
VHL (von Hippel-Lindau disease) is a rare genetic disease that can cause tumors, both benign and malignant, to develop in up to ten different organs throughout a patient's life.
Clinical Scorecard: VHL Syndrome Q&A with Roswell Park Comprehensive Cancer Center
At a Glance
Category Detail
Condition Von Hippel-Lindau Disease (VHL) Key Mechanisms Inherited mutation in the VHL gene leading to tumors and cysts in multiple organs. Target Population Individuals with a family history of tumors or those presenting with symptoms related to VHL. Care Setting VHL Clinical Care Centers
Key Highlights
VHL is the most common cause of hereditary kidney cancer. Patients often present with visual symptoms or neurologic symptoms. Multifocal tumors are common in VHL compared to sporadic cases. Genetic testing is essential for diagnosis. Management requires a multidisciplinary approach. Guideline-Based Recommendations
Diagnosis
Clinical suspicion based on symptoms and family history. Genetic testing for definitive confirmation. Management
Referral to a VHL Clinical Care Center for specialized care. Involvement of a multidisciplinary team. Monitoring & Follow-up
Regular imaging and assessments for tumor development. Risks
Increased risk of tumors in multiple organs including kidneys, eyes, and brain. Patient & Prescribing Data
Individuals diagnosed with VHL syndrome.
Management deviates from standard guidelines for sporadic cancers.
Clinical Best Practices
Refer patients to VHL Clinical Care Centers for comprehensive management. Consider family history in assessment and diagnosis. References
